Oral iron chelation therapy for thalassaemia: An uncertain scene

British Journal of Haematology

Volumn 111, Issue 1, 2000, Pages 2-5

  Pippard, M J ^a   Weatherall, D J ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Thalassaemia; Deferiprone; Desferrioxamine; Iron loading; Oral iron chelation

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

AGRANULOCYTOSIS; ARTHROPATHY; BETA THALASSEMIA; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG EFFICACY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER HISTOLOGY; LIVER INJURY; NEUTROPENIA; NOTE; PRIORITY JOURNAL; VIRUS HEPATITIS;

BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER CIRRHOSIS; PYRIDONES;

EID: 0033757846     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02406.x     Document Type: Note

References (34)

1. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial
2. Deaths in patients receiving oral iron chelator L1
3. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major
4. Results of long-term deferiprone (L1) therapy. A report by the International Study Group on Oral Iron Chelators
5. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey
6. Toxocity of oral iron chelator L1
7. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major New England Journal of Medicine
8. A multi-center safety trial of the oral iron chelator deferiprone
9. Safety profile of the oral iron chelator deferiprone: A multicentre study
10. Development of oral iron chelator L1
11. Iron chelators for thalassaemia
12. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
13. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)
14. Iron-chelation therapy with oral deferiprone - Toxicity or lack of efficacy?
15. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
16. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1
17. Deaths in patients receiving oral iron chelatos L1
18. An orally active iron chelator
19. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in thalassemia major
20. Iron-chelating therapy and the treatment of thalassemia
21. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)
22. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
23. First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine
24. Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalasemia major
25. Cardiac failure and myocardial fibrosis in a patient with thalassemia major (TM) treated with long-term deferiprone
26. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients
27. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia
28. The development of iron chelating drugs
29. Iron chelation with oral deferiprone in patients with thalassemia
30. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major
31. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
32. Iron chelation with oral deferiprone in patients with thalassemia
33. Combined therapy with deferiprone and desferrioxamine